Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Surmodics, Inc.

< Previous 1 2 Next >
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics to Participate in Upcoming Investor Conferences in March and April
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
From Surmodics, Inc.
Via Business Wire
Tickers SRDX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.